RXRX · XBRL financial data

Recursion Pharmaceuticals financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RXRX's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	10	40	45	59	75
Cost of goods and services sold	0	48	43	45	71
Research and development	135	156	241	314	475
General and administrative	58	82	111	178	177
Total operating expenses	193	—	—	—	—
Operating income (loss)	(183)	(246)	(350)	(479)	(648)
Interest expense	3	0	0	2	2
Income tax expense (benefit)	0	0	(4)	(1)	(0)
Net income (loss)	(186)	(239)	(328)	(464)	(645)
Earnings per share, basic USD per share	(1.49)	(1.36)	(1.58)	(1.69)	(1.44)
Earnings per share, diluted USD per share	(1.49)	(1.36)	(1.58)	(1.69)	(1.44)
Weighted average shares, basic millions of shares	125	176	208	274	447
Weighted average shares, diluted millions of shares	125	176	208	274	447

Fiscal years (RXRX's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	285	550	392	594	743
Short-term investments	231	0	—	—	—
Accounts receivable	0	0	—	—	—
Total current assets	535	570	438	714	813
Property and equipment, net	65	88	87	141	104
Right-of-use asset	0	33	34	66	45
Goodwill	1	1	52	149	162
Total assets	610	701	654	1,449	1,474
Accounts payable	3	5	4	22	18
Accrued liabilities	32	33	47	82	70
Total current liabilities	47	100	93	187	148
Lease liability, non-current	0	44	43	67	47
Total liabilities	67	215	190	414	343
Accumulated deficit	(400)	(640)	(968)	(1,431)	(2,076)
Total stockholders' equity	543	486	463	1,035	1,131
Total liabilities and equity	610	701	654	1,449	1,474
Common shares outstanding (cover page) millions of shares	170	191	234	397	528

Fiscal years (RXRX's year ends in late December)

In millions of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(186)	(239)	(328)	(464)	(645)
Stock-based compensation	15	28	54	82	111
Depreciation and amortization	8	12	24	36	84
Net cash from operating activities	(159)	(84)	(288)	(359)	(372)
Purchases of property and equipment	40	37	12	14	6
Net cash from investing activities	(272)	193	(10)	260	(17)
Proceeds from issuing common stock	463	144	128	300	529
Repayments of long-term debt	13	0	1	—	—
Net cash from financing activities	459	154	140	304	522
Net change in cash	28	264	(158)	202	151

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026
Bausch Health Companies	2,485	2,941	814*	374.3M	—	Q3 FY26 10-QSep 30, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Biocryst Pharmaceuticals	97	180	not reported	257.3M	—	Q3 FY26 10-QSep 30, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.